What is BPC-157 Oral (Capsule)?
This is the capsule variant of oral BPC-157, identical in principle to the tablet form (see BPC-157 Oral and the main BPC-157 entry). Some prefer capsules because they are easier to swallow or release more gently on the stomach.
Comparison
Same compound, different form
BPC-157 as injection, tablet, capsule and in the oral blend, as stated in the TPD lexicon. Tap a card to open its entry.
Simplified: capsule and tablet are the same in principle. In humans only injection or infusion has been studied so far. 6
How it works
As with the tablet: BPC-157 is associated with gastrointestinal healing and connective-tissue repair. With oral intake the effect is most plausible locally in the digestive tract, systemic absorption is limited.
The mechanism in detail is in the BPC-157 entry.
Where it acts
Where BPC-157 acted in experiments
Tap a point or a card. All sites from animal studies, there is no confirmed receptor.
- Stomach and oesophagus
Mucosal protection against alcohol and painkiller damage, sphincters strengthened (rats)2
Observed in trials - Gut
Colon-skin fistulas also healed with BPC-157 in the drinking water (rats)3
Observed in trials - Skin and wounds
Faster healing of incision, burn and diabetic wounds (rats)1
Observed in trials - Tendons and ligaments
Better healing of tendons, ligaments and muscle in animal models5
Observed in trials - Liver and kidney
Broken down in the liver, excreted via urine and bile (rats, dogs)4
Observed in trials
How to take it
Oral, usually one capsule (500mcg) per day with some water, for gastrointestinal topics often on an empty stomach.
Dosing
Dosing
Dosing, titration and syringe
Loading the dosing information …
- Getting started and stepping up, drawn as a staircase
- Units on the U-100 syringe for every step
- How long one vial lasts
What the research shows
As with the tablet: BPC-157 is broadly described preclinically (overview: Seiwerth/Sikiric, 2021), on oral bioavailability in humans the data is thin. Plausible for local gut effects, systemically the injection is the better-evidenced route.
Study results
What the trials measured
Interactive: switch tabs, tap points, show or hide arms. Arms are named relative to each other, no dosing advice.
Where the knowledge on BPC-157 comes from5
Share of the 36 studies in a systematic review (literature up to June 2024)
The only human study in the review was a retrospective analysis of knee injections: 7 of 12 people reported less pain for more than 6 months. No comparison group.
Participants by route6
Share of the 30 people from all three human studies (systematic review up to June 2026)
All three studies without a control group, the review rates the certainty of evidence as very low. There is no published human study of BPC-157 taken by mouth.
Research status
Where the research stands
Registered trials on the compound BPC-157. There are none on the capsule. The only tablet trial (NCT02637284, phase 1, started 2015) is listed with unknown status and no results. As of 26 Oct 2026. 7
- Preclinical Animal and cell studies, including dosing in drinking water
- Phase 1 1 trial, 0 completed
- Phase 2 no registered trial
- Phase 3 no registered trial
- Approval not yet
Apart from 1 phase 1 trial there is no registered trial in phase 2 or later. 7
Side effects
- Generally well tolerated.
- Solid human data are largely missing.
Tolerability
Side effects in the human studies
Out of 100 participants, how many had a treatment-related side effect. Three small studies without placebo, none with a capsule.
| Event | Participants |
|---|---|
| Treatment-related side effects6 | 0% |
Zero does not mean safe here: 30 people without a comparison group are not enough to detect rare or late side effects. A second review found no clinical safety data and warns of risks from unregulated manufacturing.65
Storage
Store dry, cool and protected from light, out of reach of children. Keep the original container closed and mind the expiry date.
